CRISPR-Cas9 based gene editing has become integral to functional genomics,  powering screens that underpin the extensive cataloguing of genomic variations associated with human disease, helping to unveil novel therapeutic targets. Still, much research is still needed to elucidate the function of many genes and gene regulatory elements. Often such screens are limited in their translatability because they are performed in models that are not well-representative of human physiology. As a result, the discovery of new druggable targets for human diseases like Alzheimer鈥檚 disease or ALS has remained challenging.

In this webinar hear from two experts who will showcase the latest advancements behind the next generation of functional genomic screens. Professor Luke Gilbert, Associate Professor at the University California San Francisco, will offer a deep dive into the new scalable and multiplexable functional genomics tools for characterising genes and gene regulatory elements encoded by the human genome. Additionally, Sejla Salic-Hainzl, Vice President of Research and Discovery at 91探花, will showcase a new advancement in iPSC-derived cell-based technologies that enable the easy and routine generation of CRISPR-based gene knockouts and functional genomic screens in physiologically relevant cell models. 

In this webinar you will discover:

• Cutting-edge research and recently published data on advanced CRISPR screening tools, including CRISPRi and CRISPRa, with insights into how these screens are being used to uncover the disease-associated function of genes and gene regulatory elements.
• New data from functional genomic screens utilising 鈥淐RISPR-ready鈥� iPSC-derived neuronal and microglial models, and discussion on how these models can enable the identification of new therapeutic targets for neurodegenerative disease.
• Insights from CRISPR experts on how these tools can be used to advance our understanding of the genetics underlying human disease towards the discovery of new, better therapeutics.